Literature summary for 3.4.21.98 extracted from

Mederacke, I.; Wedemeyer, H.; Manns, M.P.
Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection (2009), Curr. Opin. Investig. Drugs, 10, 181-189.

Search for more literature for 3.4.21.98

Inhibitors

Inhibitors	Comment	Organism	Structure
(1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide	Boceprevir: EC50 and EC90 values, determined in a bicistronic, subgenomic, cell-based replicon assay run over 72 h using Huh-7 hepatoma cells, are 200 and 400 nM, respectively. Preclinical, metabolism and pharmacokinetics data are very promising. Currently ongoing phase II clinical trials demonstrate the compound to be well tolerated	Hepacivirus C

Localization

Localization	Comment	Organism	GeneOntology No.	Textmining

Organism

Organism	UniProt	Comment	Textmining
Hepacivirus C	-	-	-

Synonyms

Synonyms	Comment	Organism
HCV NS3	-	Hepacivirus C

Ki Value [mM]

Ki Value [mM]	Ki Value maximum [mM]	Inhibitor	Comment	Organism	Structure
0.000014	-	(1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide	-	Hepacivirus C

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)